Literature DB >> 410686

Pharmacology of danazol.

G O Potts.   

Abstract

We have established that danazol is an orally active pituitary gonadotrophin inhibitory agent devoid of oestrogenic and progestational activity. This steroid has weak, impeded androgenic activity. Danazol is unique in possessing such a profound separation of pituitary gonadotrophin inhibitory activity from overt sex hormone activity. Separate studies have shown that danazol is antiandrogenic, anti-progestational and antioestrogenic. Extensive toxicological studies have established the safety of this steroid. Lastly, the metabolic studies provide convincing evidence that danazol is the active steroid.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 410686

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  6 in total

Review 1.  Pharmacology and pharmacokinetics of danazol.

Authors:  G O Potts; H P Schane; J Edelson
Journal:  Drugs       Date:  1980-05       Impact factor: 9.546

2.  Danazol activity.

Authors:  G R Daniel
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

3.  Danazol in the treatment of gynaecomastia.

Authors:  R Buckle
Journal:  Drugs       Date:  1980-05       Impact factor: 9.546

4.  Tamoxifen and fluoxymesterone versus tamoxifen and danazol in metastatic breast cancer--a randomized study.

Authors:  S M Swain; S M Steinberg; C Bagley; M E Lippman
Journal:  Breast Cancer Res Treat       Date:  1988-09       Impact factor: 4.872

5.  The effect of danazol in the MRL/lpr mouse model of autoimmune disease.

Authors:  K M Connolly; V J Stecher; B W Snyder; E Bohnet; G O Potts
Journal:  Agents Actions       Date:  1988-08

6.  Danazol treatment for advanced breast cancer.

Authors:  R C Coombes; D Perez; J C Gazet; H T Ford; T J Powles
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.